GILD dividend history
Gilead Sciences Inc. (GILD) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 DividendGilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholders of record at the close of business on March 13, 2026. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi
- Gilead Sciences Announces 2.6 Percent Increase in First Quarter 2025 DividendGilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.6% in the company's quarterly cash dividend, beginning in the first quarter of 2025. The increase will result in a quarterly dividend of $0.79 per share of common stock. The dividend is payable on March 28, 2025, to stockholders of record at the close of business on March 14, 2025. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi
- Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 DividendGilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2024. The increase will result in a quarterly dividend of $0.77 per share of common stock. The dividend is payable on March 28, 2024, to stockholders of record at the close of business on March 15, 2024. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is commi
- Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 DividendGilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.7% in the company's quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committ
- Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 DividendGilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared an increase of 2.8% in the company's quarterly cash dividend, beginning in the first quarter of 2022. The increase will result in a quarterly dividend of $0.73 per share of common stock. The dividend is payable on March 30, 2022, to stockholders of record at the close of business on March 15, 2022. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committ
- Gilead Sciences Announces Second Quarter 2021 DividendGilead Sciences, Inc. (NASDAQ:GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.71 per share of common stock for the second quarter of 2021. The dividend is payable on June 29, 2021, to stockholders of record at the close of business on June 15, 2021. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral
- Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 DividendFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 4.4% in the company’s quarterly cash dividend, beginning in the first quarter of 2021. The increase will result in a quarterly dividend of $0.71 per share of common stock. The dividend is payable on March 30, 2021, to stockholders of record at the close of business on March 15, 2021. Future dividends will be subject to Board approval. About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The comp
- Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial ResultsFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020. “Gilead continues to play a central role in the pandemic, with Veklury now treating one in two hospitalized patients in the United States. At the same time, we continue to meet the needs of people living with HIV, cancer, viral hepatitis and other conditions,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These